Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor used to treat high blood pressure (hypertension) and congestive heart failure in adults and children aged 6 years and older. It is a phosphinic acid-containing ester prodrug that is rapidly hydrolyzed in the body to its active metabolite, fosinoprilat. Fosinoprilat acts as a specific competitive inhibitor of ACE, blocking the conversion of angiotensin I to angiotensin II—a potent vasoconstrictor involved in blood pressure regulation via the renin-angiotensin-aldosterone system (RAAS). By inhibiting ACE, fosinopril decreases levels of angiotensin II, leading to vasodilation, reduced aldosterone secretion, lower blood pressure, and decreased cardiac workload. This mechanism also helps slow progression of renal disease in hypertensive patients with diabetes mellitus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fosinopril.